Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 265-110-5 | CAS number: 64742-10-5 A complex combination of hydrocarbons obtained as the extract from a solvent extraction process. It consists predominantly of aromatic hydrocarbons having carbon numbers predominantly higher than C25.
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: dermal
Administrative data
- Endpoint:
- sub-chronic toxicity: dermal
- Type of information:
- migrated information: read-across based on grouping of substances (category approach)
- Adequacy of study:
- supporting study
- Study period:
- 1987-11-17 to 1988-02-18
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: This study is classified as reliable without restrictions because it closely followed OECD Guideline 411 and appears to be GLP compliant
- Justification for type of information:
- Concawe believes that dermal is the most relevant exposure route, and is sufficiently robust, to identify any potential hazards from repeated exposures to petroleum products to be able to adequately manage the potentially associated risks.
This study will be replaced as Key study by the 90-day dermal study currently being proposed.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 990
- Report date:
- 1990
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 411 (Subchronic Dermal Toxicity: 90-Day Study)
- Deviations:
- yes
- Remarks:
- Either one or two dose levels were used instead of the requisite three dose levels; a limit test corresponding to a dose level of at least 1000mg/kg-body weight was not conducted
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- 64742-10-5
- Cas Number:
- 64742-10-5
- IUPAC Name:
- 64742-10-5
- Reference substance name:
- Bright Stock Extract-BSE Australia
- IUPAC Name:
- Bright Stock Extract-BSE Australia
- Reference substance name:
- BSS Furfural Extract:BSE Statjford
- IUPAC Name:
- BSS Furfural Extract:BSE Statjford
- Reference substance name:
- Extrait BSS: BSE Ninian
- IUPAC Name:
- Extrait BSS: BSE Ninian
- Details on test material:
- - Name of test material (as cited in study report): Mobilsol 40, Bright Stock Extract, BSS Furfural Extract, Extrait BSS
- Substance type: Residual Aromatic Extract
Constituent 1
Constituent 2
Constituent 3
Constituent 4
Test animals
- Species:
- rat
- Strain:
- other: N(SD)fBR
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Taconic Farms, Germantown, NY
- Age at study initiation: 50 days
- Weight at study initiation: Data not reported
- Fasting period before study: Data not reported
- Housing: Data not specified
- Diet (e.g. ad libitum): Purina Certified Lab Chow, ad libitum
- Water (e.g. ad libitum): Ad libitum
- Acclimation period: 2 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 to 22
- Humidity (%): 40 to 60
- Air changes (per hr): Data not reported
- Photoperiod (hrs dark / hrs light): 12 hrs dark/12 hrs light
Administration / exposure
- Type of coverage:
- open
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- TEST SITE
- Area of exposure: Dorsal trunk
- % coverage: Data not reported
- Type of wrap if used: Test material was not covered
- Time intervals for shavings or clipplings: At least once a week
REMOVAL OF TEST SUBSTANCE
- Washing (if done): Test materials wiped using gauze pads
- Time after start of exposure: Once per week
TEST MATERIAL
- Amount(s) applied (volume or weight with unit): Volume not specified; however volume applied was adjusted based on the most recent body weight data
- Constant volume or concentration used: No, volume was adjusted based on the most recent body weight data
USE OF RESTRAINERS FOR PREVENTING INGESTION: Yes; Cardboard Elizabethan-style collars lined with latex tubing - Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 5 days/week for 13 weeks
- Frequency of treatment:
- Though not specified, the test materials were applied once per day
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
500 and 2000 mg/kg bw Mobilsol 40
Basis:
nominal per unit body weight
- Remarks:
- Doses / Concentrations:
2000 mg/kg bw Bright Stock Extract, BSS Furfural Extract, Extrait BSS
Basis:
nominal per unit body weight
- No. of animals per sex per dose:
- 10 males, 10 females
- Control animals:
- yes
- Details on study design:
- - Dose selection rationale: Data not reported
- Rationale for animal assignment (if not random): Randomly assigned using Grosse system computer program - Positive control:
- No used
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: No data
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Once per day
DERMAL IRRITATION (if dermal study): Yes
- Time schedule for examinations: Examined once a week
BODY WEIGHT: Yes
- Time schedule for examinations: Animals were weighed a week prior to study initiation, immediately following first dose and once a week following dosing until study termination
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: No data
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No data
WATER CONSUMPTION: No data
OPHTHALMOSCOPIC EXAMINATION: No data
HAEMATOLOGY: Yes
- Time schedule for collection of blood: Blood samples were collected during weeks 5 and 13 from all animals within a two-day period
- Anaesthetic used for blood collection: Yes: diethyl ether
- Animals fasted: Yes
- How many animals: 5/sex
- Parameters checked in table [No.?] were examined: Fifteen haematological parameters were checked
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: Week 5 and 13
- Animals fasted: No data
- How many animals: 9-10 animals in untreated control group; 2 in the 500 mg/kg-BW group; 3 in the 2000 mg/kg-BW group
- Parameters checked in table [No.?] were examined: In all 15 hematological parameters were measured
URINALYSIS: Yes
- Time schedule for collection of urine: No data
- Metabolism cages used for collection of urine: No data
- Animals fasted: No data
- Parameters checked in table [No.?] were examined. No data
NEUROBEHAVIOURAL EXAMINATION: No data
- Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: No data - Other examinations:
- Spermatozoa and spermatid evaluations were conduced along with measurement of absolute and relative organ weights.
- Statistics:
- Quantitative data were analyzed by parametric methods. Analysis of variance (ANOVA) and associated F-test, followed by Dunnett’s test or Tukey’s multiple range tests were performed, provided there was statistical significance in ANOVA. Differences between control and treated animals were considered to be significant only if the p-value was less than 5%.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Dermal irritation:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- effects observed, treatment-related
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- not specified
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not specified
- Details on results:
- CLINICAL SIGNS AND MORTALITY: There was no mortality as a result of exposure to the four BSEs; no adverse clinical signs were reported
BODY WEIGHT AND WEIGHT GAIN: No adverse effects on body weight gain was reported
FOOD CONSUMPTION: No data
FOOD EFFICIENCY: No data
WATER CONSUMPTION: No data
OPHTHALMOSCOPIC EXAMINATION: No data
HAEMATOLOGY: Changes in hematological parameters were noted in treated females, but not males. At 13 weeks, decreases in hematological parameters were noted in RBCs and hematocrit in females treated with Mobilsol 40, RBCs, hemoglobin, and hematocrit in BSE Australia, and RBC, hemoglobin, and hematocrit in BSE Statjford (only females were exposed for this BSE). These parameters were statistically significant compared to the concurrent controls.
CLINICAL CHEMISTRY: Mobilsol 40, BSE Statjford, and BSE Ninian slightly affected the normal serum chemistry of treated rats. The serum chemistry of animals exposed to BSE Australia was more adverse compared to animals exposed to other BSEs.
URINALYSIS: No adverse effects
NEUROBEHAVIOUR: No data
ORGAN WEIGHTS: Liver weights of male rats treated with Mobilsol 40 were increased in the 2000 mg/kg-day group and in male and female rats treated with 2000 mg/kg-day BSE Australia. The study authors reported that the increase in liver weight was more of an adaptive response rather than an adverse effect.
GROSS PATHOLOGY: No remarkable observations were noted
HISTOPATHOLOGY: NON-NEOPLASTIC: No treatment related changes were noted.
HISTOPATHOLOGY: NEOPLASTIC (if applicable): No data
HISTORICAL CONTROL DATA (if applicable)
OTHER FINDINGS
Effect levels
open allclose all
- Dose descriptor:
- NOAEL
- Remarks:
- Mobilsol 40
- Effect level:
- 500 mg/kg bw/day (nominal)
- Sex:
- female
- Basis for effect level:
- other: overall effects Haematology; clinical chemistry; organ weights
- Dose descriptor:
- LOEL
- Remarks:
- BSE Australia, BSE Ninian, BSE Statjford
- Effect level:
- 2 000 mg/kg bw/day (nominal)
- Sex:
- male/female
- Basis for effect level:
- other: overall effects Haematology; clinical chemistry; organ weights
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Liver weights of male rats treated with Mobilsol 40 were increased in the 2000 mg/kg-day group and in male and female rats treated with 2000 mg/kg-day BSE Australia. The study authors reported that the increase in liver weight was more of an adaptive response rather than an adverse effect.
No signs of skin irritation were reported as result of exposure to the four BSEs. No adverse clinical signs were attributed as a result of exposure to the test materials. Body weight gains were normal in all rats treated with the four BSEs. Urinalyses and sperm evaluations were not impacted as a result of exposure to the test materials. No histopathological changes were noted in the reproductive organs of male or female rats. Further, neither epididymal spermatozoa morphology and count nor testicular spermatid counts were affected by treatment with RAEs as shown in the table.
Table 1. Summaries of data on reproductive organs from subchronic studies with RAEs (CAS RN. 64742-10-5), derived from Mobil, 1990. |
|||
Test Material |
Route, Species, Doses, Exposure Regimen |
Endpoints |
Results |
Mobilsol 40
|
Dermal. Male and female rats. 0, 500, 2000 mg/kg on 5 d/wk for 13 wk. |
Full necropsy. Weights of testes, prostate, epididymides, ovaries, and uterus. Histopathology of testes and ovaries. Weight of testicular parenchyma and cauda epididymis. Number of testicular sperm and number/g testis. Number and morphology of epididymal sperm, number/g cauda. |
No treatment-related effect noted. |
BSE - Australia |
Dermal. Male and female rats. 0, 2000 mg/kg on 5 d/wk for 13 wk. |
Full necropsy. Weights of testes, prostate, epididymides, ovaries, and uterus. Histopathology of testes and ovaries. Weight of testicular parenchyma and cauda epididymis. Number of testicular sperm and number/g testis. Number and morphology of epididymal sperm, number/g cauda. |
No treatment-related effect noted. |
BSE – Ninian |
Dermal. Male rats. 2000 mg/kg on 5 d/wk for 13 wk. |
Full necropsy. Weights of testes, prostate, and epididymides. Histopathology of testes. |
No treatment-related effect noted. |
BSE-Statfjord |
Dermal. Female rats. 2000 mg/kg on 5 d/wk for 13 wk. |
Full necropsy. Weights of ovaries and uterus. Histopathology of ovaries. |
No treatment-related effect noted. |
Changes in hematological parameters were noted in treated females, but not males. At 13 weeks, significant decreases in hematological parameters, compared to the control group, were noted in red blood cells (RBCs) and hematocrit in females treated with Mobilsol 40, RBCs, hemoglobin, and hematocrit in BSE Australia, and RBC, hemoglobin, and hematocrit in BSE Statjford (only females were exposed for this BSE).
Mobilsol 40, BSE Statjford, and BSE Ninian slightly affected the normal serum chemistry of treated rats. The serum chemistry of animals exposed to BSE Australia was more adverse compared to animals exposed to other BSEs. In Mobilsol 40, glucose, albumin, calcium (in males), glucose, and sorbitol dehydrogenase (SDH) (females) were significantly different from the control group. Animals treated with BSE Australia showed significant differences in urea nitrogen, creatinine, total protein, albumin, albumin/globulin ratio and SDH (males) levels compared to the concurrent controls. Alkaline phosphatase, calcium, and SDH levels were significantly different compared to the controls in animals treated with BSE Statjford (only females were treated with this BSE). Animals treated with BSE Ninian (only male rats were exposed to this BSE) exhibited significant changes in uric acid, albumin, calcium, inorganic phosphorus, chloride, and SDH compared to the concurrent controls.
Liver weights of male rats treated with Mobilsol 40 were increased in the 2000 mg/kg-day group and in male and female rats treated with 2000 mg/kg-day BSE Australia. The study authors reported that the increase in liver weight was more of an adaptive response rather than an adverse effect.
Based on these results, the study authors concluded that the No-Observed-Adverse-Level (NOAEL) for Mobilsol 40 is 500 mg/kg-day. A NOAEL of < 2000 mg/kg-day could not be clearly established for the BSE Australia, Ninian and Statjford, since only a single dose level was evaluated for these three extracts.
Applicant's summary and conclusion
- Conclusions:
- The study authors concluded that the No-Observed-Adverse-Level (NOAEL) for Mobilsol 40 is 500 mg/kg-day. A NOAEL of < 2000 mg/kg-day could not be clearly established for the BSE Australia, Ninian and Statjford, since only a single dose level was evaluated for these three extracts.
- Executive summary:
In a repeated dose dermal study, ten male and female [N(SD)fBR] rats were dosed dermally with four Bright Stock Extracts (BSEs) comprised of Mobilsol 40, BSE Australia, BSE Ninian, and BSE Statfjord 5 days/week for 13 weeks. A group of ten male and female rats served as the control group. Prior to test material(s) application, each animal was clipped free of hair from the entire dorsal trunk area. Hair was re-clipped as required at least once per week. Mobilsol was applied at a dose of 500 and 2000 mg/kg-day, whereas, the other three BSE extracts were applied at a dose of 2000 mg/kg-day. The exposure sites were left uncovered. All treated and control rats were fitted with a cardboard Elizabethan-style collars lined with latex tubing to minimize ingestion of the test materials. Collars were fitted on the rats several days prior to dose administration and replaced as needed during the dosing period.
No signs of skin irritation were reported as result of exposure to the four BSEs. No adverse clinical signs were attributed as a result of exposure to the test materials. Body weight gains were normal in all rats treated with the four BSEs. Urinalyses and sperm evaluations were not impacted as a result of exposure to the test materials.
Changes in hematological parameters were noted in treated females, but not males. At 13 weeks, significant decreases in hematological parameters, compared to the control group, were noted in red blood cells (RBCs) and hematocrit in females treated with Mobilsol 40, RBCs, hemoglobin, and hematocrit in BSE Australia, and RBC, hemoglobin, and hematocrit in BSE Statjford (only females were exposed for this BSE).
Mobilsol 40, BSE Statjford, and BSE Ninian slightly affected the normal serum chemistry of treated rats. The serum chemistry of animals exposed to BSE Australia was more adverse compared to animals exposed to other BSEs. In Mobilsol 40, glucose, albumin, calcium (in males), glucose, and sorbitol dehydrogenase (SDH) (females) were significantly different from the control group. Animals treated with BSE Australia showed significant differences in urea nitrogen, creatinine, total protein, albumin, albumin/globulin ratio and SDH (males) levels compared to the concurrent controls. Alkaline phosphatase, calcium, and SDH levels were significantly different compared to the controls in animals treated with BSE Statjford (only females were treated with this BSE). Animals treated with BSE Ninian (only male rats were exposed to this BSE) exhibited significant changes in uric acid, albumin, calcium, inorganic phosphorus, chloride, and SDH compared to the concurrent controls.
Liver weights of male rats treated with Mobilsol 40 were increased in the 2000 mg/kg-day group and in male and female rats treated with 2000 mg/kg-day BSE Australia. The study authors reported that the increase in liver weight was more of an adaptive response rather than an adverse effect.
Based on these results, the study authors concluded that the No-Observed-Adverse-Level (NOAEL) for Mobilsol 40 is 500 mg/kg-day. A NOAEL of < 2000 mg/kg-day could not be clearly established for the BSE Australia, Ninian and Statjford since only a single dose level was evaluated for these three extracts.
This study received a Klimisch score of 1 and is classified as “reliable without restrictions” it closely followed OECD Guideline 411 and appears to be GLP compliant.
This study will influence the DNEL(s).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.